(Q39906851)

English

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

author name string

Philipp Baumann

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sonja Mandl-Weber

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Fuat Oduncu

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Ralf Schmidmaier

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

27 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Experimental Cell Research

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

315

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

485-497

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

PI3K/Akt signalling pathway and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Akt signaling and cancer: surviving but not moving on.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

CDK2 regulation through PI3K and CDK4 is necessary for cell cycle progression of primary rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Induction of NF-kappaB by the Akt/PKB kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

p70s6k function is essential for G1 progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.11.007

7 January 2021

Identifiers

10.1016/J.YEXCR.2008.11.007

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39906851&oldid=1876792116"